Cargando…

Angiotensin converting enzyme defects in shock: implications for future therapy

Detalles Bibliográficos
Autores principales:	Chawla, Lakhmir S., Chen, Steve, Bellomo, Rinaldo, Tidmarsh, George F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204272/ https://www.ncbi.nlm.nih.gov/pubmed/30368243 http://dx.doi.org/10.1186/s13054-018-2202-y

Ejemplares similares

Broad spectrum vasopressors: a new approach to the initial management of septic shock?
por: Chawla, Lakhmir S., et al.
Publicado: (2019)

Why the renin–angiotensin–aldosterone system (RAAS) in critically ill patients can no longer be ignored
por: Zarbock, Alexander, et al.
Publicado: (2021)

The use of angiotensin II in distributive shock
por: Chawla, Lakhmir S., et al.
Publicado: (2016)

Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock
por: Bellomo, Rinaldo, et al.
Publicado: (2020)

Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial
por: Bellomo, Rinaldo, et al.
Publicado: (2020)

Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II
por: Tumlin, James A., et al.
Publicado: (2018)

Angiotensin-converting enzyme 2 and new insights into the renin–angiotensin system
por: Lambert, Daniel W., et al.
Publicado: (2008)

Commentary to Angiotensin-Converting-Enzyme 2 and Renin–Angiotensin System Inhibitors in COVID-19: An Update
por: Ferri, Claudio, et al.
Publicado: (2021)

Theoretical Assessment of Therapeutic Effects of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors on COVID-19
por: Khalili, Azadeh, et al.
Publicado: (2021)

How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trial
por: Bonarjee, Vernon VS, et al.
Publicado: (2001)

Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and COVID-19: Demonstrating the Actionability of Real-World Evidence
por: Hennessy, Sean, et al.
Publicado: (2020)

On the essentiality of the angiotensin converting enzyme 2 receptor for SARS‐CoV‐2 infection and the potential of soluble angiotensin converting enzyme 2 proteins as universal approach for variants causing COVID‐19
por: Hassler, Luise, et al.
Publicado: (2022)

Reply to Picod et al.: Alteration of the Renin–Angiotensin–Aldosterone System in Shock: Role of the Dipeptidyl Peptidase 3
por: Chawla, Lakhmir S.
Publicado: (2021)

Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial
por: Ham, Kealy R., et al.
Publicado: (2019)

Angiotensin‐converting enzyme 2 as a versatile player in the management of coronavirus disease 2019
por: Amano, Tetsuya
Publicado: (2020)

Increasing angiotensin-converting enzyme concentrations and absent angiotensin-converting enzyme activity are associated with adverse kidney outcomes in pediatric septic shock
por: Pode-Shakked, Naomi, et al.
Publicado: (2023)

Angiotensin Converting Enzymes
por: Wong, Marty K.S.
Publicado: (2016)

Angiotensin converting enzyme
por: Wong, Marty Kwok-Shing
Publicado: (2021)

Angiotensin‐converting enzyme 2 in the brain: properties and future directions
por: Xia, Huijing, et al.
Publicado: (2008)

Angiotensin-Converting Enzyme-2
por: Clarke, Nicola E., et al.
Publicado: (2013)

Angiotensin-converting enzyme activity and inhibition in dogs with cardiac disease and an angiotensin-converting enzyme polymorphism
por: Meurs, Kathryn M, et al.
Publicado: (2017)

Dietary Potassium Downregulates Angiotensin-I Converting Enzyme, Renin, and Angiotensin Converting Enzyme 2
por: Vio, Carlos P., et al.
Publicado: (2020)

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Synthetic Human Angiotensin II in Pediatric Patients With Vasodilatory Shock: A Report on Two Patients
por: Bailey, Dwight M., et al.
Publicado: (2019)

Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Gersh, Felice L.
Publicado: (2020)

Regulation of Angiotensin- Converting Enzyme 2 in Obesity: Implications for COVID-19
por: Al Heialy, Saba, et al.
Publicado: (2020)

Angiotensin-Converting Enzyme Inhibitors and Angioedema
por: Sánchez-Borges, Mario, et al.
Publicado: (2010)

Angiotensin-converting Enzyme Genetic Polymorphism
por: Wiwanitkit, Somsri, et al.
Publicado: (2014)

Reduced urinary levels of angiotensin-converting enzyme 2 activity predict acute kidney injury in critically ill patients
por: Bitker, Laurent, et al.
Publicado: (2023)

Angiotensin-I-converting enzyme and its relatives
por: Riordan, James F
Publicado: (2003)

In reply—Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Renin‐angiotensin aldosterone profile before and after angiotensin‐converting enzyme‐inhibitor administration in dogs with angiotensin‐converting enzyme gene polymorphism
por: Adin, Darcy, et al.
Publicado: (2020)

Angiotensin Converting Enzyme-2 (ACE-2) role in disease and future in research
por: Abdul-Hafez, Amal, et al.
Publicado: (2021)

Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?
por: Tscharre, Maximilian, et al.
Publicado: (2020)

Intrarenal Distributions and Changes of Angiotensin-Converting Enzyme and Angiotensin-Converting Enzyme 2 in Feline and Canine Chronic Kidney Disease
por: MITANI, Sawane, et al.
Publicado: (2013)

Management of hypertension in patients with COVID-19: Implication of angiotensin-converting enzyme 2
por: Guang-Hong, Jia, et al.
Publicado: (2021)

Angiotensin-Converting Enzyme 2: The First Decade
por: Clarke, Nicola E., et al.
Publicado: (2012)

Serum Angiotensin Converting Enzyme in Pemphigus Vulgaris
por: Robati, Reza M, et al.
Publicado: (2014)

Angiotensin Converting Enzyme Activity in Alopecia Areata
por: Namazi, Mohammad Reza, et al.
Publicado: (2014)

Angiotensin-converting enzyme 2 in lung diseases
por: Kuba, Keiji, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_tkk18rdc2mfbssiuq2o0k1jj9q